Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon

Cesare Mazzaro; Francesca Zorat; Consuelo Comar; Fabiana Nascimben; Dario Bianchini; Stefano Baracetti; Carlo Donada; Valter Donadon; Gabriele Pozzato

Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon

Cesare Mazzaro, Francesca Zorat, Consuelo Comar, Fabiana Nascimben, Dario Bianchini, Stefano Baracetti, Carlo Donada, Valter Donadon, Gabriele Pozzato

Centro di Riferimento Oncologico

Research output: Contribution to journal › Article › peer-review

Abstract

Objective. Only a small fraction of patients with hepatitis C virus (HCV) positive mixed cryoglobulinemia achieve longterm recovery after interferon (IFN) therapy; we evaluated the effectiveness and safety of combination therapy (interferon plus ribavirin) in nonresponders or those who relapsed after one or more courses of IFN. Methods. Twenty-seven patients with HCV positive mixed cryoglobulinemia were studied. All were treated with IFN-α2b (3 MU 3 times weekly) for one year, plus daily oral ribavirin 1000 or 1200 mg. Results. Five patients (18.5%) obtained complete recovery from viral infection and from all signs and symptoms of disease. During treatment, most patients (85%) improved clinically. All 5 responders were "relapsers" to the first treatment(s). Conclusion. Combination therapy of IFN plus ribavirin could be useful for patients with mixed cryoglobulinemia resistant to IFN as monotherapy.

Original language	English
Pages (from-to)	1775-1781
Number of pages	7
Journal	Journal of Rheumatology
Volume	30
Issue number	8
Publication status	Published - Aug 1 2003

Keywords

α-Interferon
Hepatitis C virus
Mixed cryoglobulinemia
Non-Hodgkin's lymphoma
Ribavirin

ASJC Scopus subject areas

Immunology
Rheumatology

Fingerprint Dive into the research topics of 'Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon'. Together they form a unique fingerprint.

Cite this

Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. / Mazzaro, Cesare; Zorat, Francesca; Comar, Consuelo; Nascimben, Fabiana; Bianchini, Dario; Baracetti, Stefano; Donada, Carlo; Donadon, Valter; Pozzato, Gabriele.

In: Journal of Rheumatology, Vol. 30, No. 8, 01.08.2003, p. 1775-1781.

Research output: Contribution to journal › Article › peer-review

@article{d87045cf67574b93a9942bbb67e41bd7,

title = "Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon",

abstract = "Objective. Only a small fraction of patients with hepatitis C virus (HCV) positive mixed cryoglobulinemia achieve longterm recovery after interferon (IFN) therapy; we evaluated the effectiveness and safety of combination therapy (interferon plus ribavirin) in nonresponders or those who relapsed after one or more courses of IFN. Methods. Twenty-seven patients with HCV positive mixed cryoglobulinemia were studied. All were treated with IFN-α2b (3 MU 3 times weekly) for one year, plus daily oral ribavirin 1000 or 1200 mg. Results. Five patients (18.5%) obtained complete recovery from viral infection and from all signs and symptoms of disease. During treatment, most patients (85%) improved clinically. All 5 responders were {"}relapsers{"} to the first treatment(s). Conclusion. Combination therapy of IFN plus ribavirin could be useful for patients with mixed cryoglobulinemia resistant to IFN as monotherapy.",

keywords = "α-Interferon, Hepatitis C virus, Mixed cryoglobulinemia, Non-Hodgkin's lymphoma, Ribavirin",

author = "Cesare Mazzaro and Francesca Zorat and Consuelo Comar and Fabiana Nascimben and Dario Bianchini and Stefano Baracetti and Carlo Donada and Valter Donadon and Gabriele Pozzato",

year = "2003",

month = aug,

day = "1",

language = "English",

volume = "30",

pages = "1775--1781",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "8",

}

TY - JOUR

T1 - Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon

AU - Mazzaro, Cesare

AU - Zorat, Francesca

AU - Comar, Consuelo

AU - Nascimben, Fabiana

AU - Bianchini, Dario

AU - Baracetti, Stefano

AU - Donada, Carlo

AU - Donadon, Valter

AU - Pozzato, Gabriele

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Objective. Only a small fraction of patients with hepatitis C virus (HCV) positive mixed cryoglobulinemia achieve longterm recovery after interferon (IFN) therapy; we evaluated the effectiveness and safety of combination therapy (interferon plus ribavirin) in nonresponders or those who relapsed after one or more courses of IFN. Methods. Twenty-seven patients with HCV positive mixed cryoglobulinemia were studied. All were treated with IFN-α2b (3 MU 3 times weekly) for one year, plus daily oral ribavirin 1000 or 1200 mg. Results. Five patients (18.5%) obtained complete recovery from viral infection and from all signs and symptoms of disease. During treatment, most patients (85%) improved clinically. All 5 responders were "relapsers" to the first treatment(s). Conclusion. Combination therapy of IFN plus ribavirin could be useful for patients with mixed cryoglobulinemia resistant to IFN as monotherapy.

AB - Objective. Only a small fraction of patients with hepatitis C virus (HCV) positive mixed cryoglobulinemia achieve longterm recovery after interferon (IFN) therapy; we evaluated the effectiveness and safety of combination therapy (interferon plus ribavirin) in nonresponders or those who relapsed after one or more courses of IFN. Methods. Twenty-seven patients with HCV positive mixed cryoglobulinemia were studied. All were treated with IFN-α2b (3 MU 3 times weekly) for one year, plus daily oral ribavirin 1000 or 1200 mg. Results. Five patients (18.5%) obtained complete recovery from viral infection and from all signs and symptoms of disease. During treatment, most patients (85%) improved clinically. All 5 responders were "relapsers" to the first treatment(s). Conclusion. Combination therapy of IFN plus ribavirin could be useful for patients with mixed cryoglobulinemia resistant to IFN as monotherapy.

KW - α-Interferon

KW - Hepatitis C virus

KW - Mixed cryoglobulinemia

KW - Non-Hodgkin's lymphoma

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=0043031300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043031300&partnerID=8YFLogxK

M3 - Article

C2 - 12913934

AN - SCOPUS:0043031300

VL - 30

SP - 1775

EP - 1781

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 8

ER -